Patient
SITE005-0131
completed Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE005 (FRA) (Dr. Muller)
consented 2026-01-30
Adverse events
4
Serious AEs
0
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 4
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-12-15 (study day 126); relationship: not assessed
Grade 3 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-12-09 (study day 120); relationship: RELATED
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-11-30 (study day 111); relationship: not assessed
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-10-05 (study day 55); relationship: not assessed
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.